RxDoctor Payments Data

Manickam Ganesh, MD

Geriatric Medicine · West Orange, NJNPI 1962419838

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 77 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 16 manufacturers reported payments, led by Novo Nordisk at 40.2% of the total. Reporting peaked in 2019 at $545 and has fallen 97.0% since, to $16 in 2025.

$1,040in general payments, 2019–2025

Across 77 payments — averaging $13.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$418
  • AbbVie$94
  • Travere Therapeutics, Inc.$90
  • Lilly USA, LLC$84
  • Merck$84
  • Novartis$68
  • plus $201 from 10 others

What the payments were for

  • Food & beverage$1,040100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,040 in reported general payments places this provider in the 65th percentile of 165 geriatric medicine providers in New Jersey.

See all geriatric medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$193,448
Medicare patients
112
Services billed
1,258

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VelphoroSucroferric Oxyhydroxide15$81,927
JanuviaSitagliptin Phosphate23$24,272
EliquisApixaban35$17,802
EntrestoSacubitril/Valsartan13$12,221
OzempicSemaglutide13$12,221
FarxigaDapagliflozin Propanediol11$5,993
Sevelamer Carbonate57$4,330
Lantus SolostarInsulin Glargine,hum.Rec.Anlog27$3,166
Metformin Hcl23$2,099
Atorvastatin Calcium154$1,505
Midodrine Hcl28$1,407
Calcium Acetate19$1,356
Divalproex Sodium35$1,271
Silodosin13$1,035
Cephalexin31$979

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia$84$24,27223 claims
PfizerEliquis$13$17,80235 claims
NovartisEntresto$68$12,22113 claims
Novo NordiskOzempic$418$12,22113 claims
AstraZenecaFarxiga$15$5,99311 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 165 geriatric medicine providers in New Jersey.

Other geriatric medicine in West Orange

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →